| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00774-008-0012-Z |
| P8608 | Fatcat ID | release_bl23tpkgxbbebjrxso76ascdaq |
| P698 | PubMed publication ID | 19057841 |
| P2093 | author name string | Toshio Matsumoto | |
| Masahiro Abe | |||
| Shuji Ozaki | |||
| Shinsuke Kido | |||
| Kenji Hiura | |||
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Novel therapies targeting the myeloma cell and its bone marrow microenvironment | Q34461557 | ||
| RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 | ||
| Targeting the bone marrow microenvironment in hematologic malignancies | Q35800905 | ||
| Intracellular signalling controlling integrin activation in lymphocytes | Q36167584 | ||
| Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 | ||
| The role of the bone marrow microenvironment in multiple myeloma | Q36246522 | ||
| Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism | Q36350921 | ||
| A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells | Q39100887 | ||
| Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis | Q40557146 | ||
| Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. | Q40858675 | ||
| Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. | Q40910768 | ||
| Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. | Q41065416 | ||
| 'Role of bone marrow stromal cells in the growth of human multiple myeloma | Q41134325 | ||
| Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. | Q41152758 | ||
| Development of an in vivo model of human multiple myeloma bone disease | Q41228326 | ||
| Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines | Q41328166 | ||
| A novel membrane antigen selectively expressed on terminally differentiated human B cells. | Q41441966 | ||
| Role of the bone marrow microenvironment in multiple myeloma | Q44202437 | ||
| Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms | Q44452179 | ||
| Cancer and the microenvironment: myeloma-osteoclast interactions as a model | Q44802876 | ||
| Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion | Q47371978 | ||
| Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma | Q47965350 | ||
| T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ | Q59068529 | ||
| Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma | Q73971509 | ||
| Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells | Q74511360 | ||
| Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma | Q74676116 | ||
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment | Q77337113 | ||
| Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells | Q77343472 | ||
| Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival | Q82481954 | ||
| BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma | Q83159481 | ||
| P433 | issue | 1 | |
| P921 | main subject | inflammation | Q101991 |
| macrophage | Q184204 | ||
| P304 | page(s) | 16-23 | |
| P577 | publication date | 2008-12-05 | |
| P1433 | published in | Journal of Bone and Mineral Metabolism | Q15767236 |
| P1476 | title | Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production | |
| P478 | volume | 27 |
| Q35612803 | Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype |
| Q24701763 | Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection |
| Q89878681 | Bone Marrow Stromal Cells Drive Key Hallmarks of B Cell Malignancies |
| Q38843253 | Bone metastasis: the importance of the neighbourhood. |
| Q55395268 | Bone-targeted agents in multiple myeloma. |
| Q36206430 | Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma |
| Q37879210 | CCR1 as a target for multiple myeloma |
| Q57284923 | Chemokine analysis as a novel diagnostic modality in the early prediction of the outcome of non-union therapy: a matched pair analysis |
| Q28477867 | Computational modeling of interactions between multiple myeloma and the bone microenvironment |
| Q37499263 | Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins |
| Q39524246 | Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma |
| Q57904674 | Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma |
| Q39758292 | Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma |
| Q37734280 | Mechanism of action of immunomodulatory agents in multiple myeloma |
| Q36673755 | Novel Bruton's tyrosine kinase inhibitors currently in development |
| Q37822742 | Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. |
| Q53238656 | Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. |
| Q37946702 | Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma |
| Q28473419 | Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth |
| Q39472801 | The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications |
| Q50064432 | Tooth Extraction Locally Stimulates Proliferation of Multiple Myeloma in a Patient with Mandibular Localizations |
| Q27316139 | Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma |
Search more.